These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

524 related items for PubMed ID: 11498741

  • 21. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321.
    Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD, McCoy J, Moore DF, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC.
    J Clin Oncol; 2006 Feb 20; 24(6):929-36. PubMed ID: 16432076
    [Abstract] [Full Text] [Related]

  • 22. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
    Kuruvilla J, Shepherd JD, Sutherland HJ, Nevill TJ, Nitta J, Le A, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Toze CL, Smith CA, Barnett MJ, Song KW.
    Biol Blood Marrow Transplant; 2007 Aug 20; 13(8):925-31. PubMed ID: 17640596
    [Abstract] [Full Text] [Related]

  • 23. High-dose therapy autotransplantation/intensification vs continued standard chemotherapy in multiple myeloma in first remission. Results of a non-randomized study from a single institution.
    Bladé J, Esteve J, Rives S, Martínez C, Rovira M, Urbano-Ispizua A, Marín P, Carreras E, Montserrat E.
    Bone Marrow Transplant; 2000 Oct 20; 26(8):845-9. PubMed ID: 11081383
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. High-dose therapy and autologous stem cell transplantation in patients with diffuse large B-cell lymphoma in first complete or partial remission.
    Papajik T, Raida L, Faber E, Vondrakova J, Prochazka V, Kubova Z, Skoumalova I, Jarosova M, M LK, Paucek B, Myslivecek M, Neoral C, Oral I, Jarkovsky J, Dusek L, Indrak K.
    Neoplasma; 2008 Oct 20; 55(3):215-21. PubMed ID: 18348654
    [Abstract] [Full Text] [Related]

  • 31. Induction chemotherapy improved outcomes of patients with resectable esophageal cancer who received chemoradiotherapy followed by surgery.
    Jin J, Liao Z, Zhang Z, Ajani J, Swisher S, Chang JY, Jeter M, Guerrero T, Stevens CW, Vaporciyan A, Putnam J, Walsh G, Smythe R, Roth J, Yao J, Allen P, Cox JD, Komaki R.
    Int J Radiat Oncol Biol Phys; 2004 Oct 01; 60(2):427-36. PubMed ID: 15380576
    [Abstract] [Full Text] [Related]

  • 32. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB.
    Cancer Chemother Pharmacol; 2002 May 01; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. [Renal disease in myeloma. Role of the tumor cell mass (author's transl)].
    San Miguel J, Batlle J, Alberca I, Moraleda JM, López Borrasca A.
    Med Clin (Barc); 1981 Apr 25; 76(8):347-9. PubMed ID: 7253752
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.